# A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

> **NCT04636515** · PHASE2 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 80 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Urothelial Cell Carcinoma

## Interventions

- **DRUG:** F520

## Key facts

- **NCT ID:** NCT04636515
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2022-03
- **Final completion:** 2022-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636515, "A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04636515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*